[go: up one dir, main page]

Qiu et al., 1996 - Google Patents

Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients

Qiu et al., 1996

View PDF
Document ID
11058587739518471883
Author
Qiu X
Lu D
Zhou J
Wang J
Yang J
Meng P
Jerry L
Publication year
Publication venue
Chinese medical journal

External Links

Snippet

OBJECTIVE To examine the safety and effects of gene therapy for hemophilia B by implantation of autologous fibroblasts genetically modified to secrete clotting factor IX (hFIX). PATIENTS AND METHODS Two hemophilia B patients LD and LW were selected from one …
Continue reading at mednexus.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Qiu et al. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients
AU659824B2 (en) Retroviral vectors useful for gene therapy
Morganti et al. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease
JP3203599B2 (en) Infectious protein delivery system
Halbert et al. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration
Madry et al. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage
DE69534792T2 (en) ADMINISTRATION OF COMPLETE FACTOR VIII WITH THE HELP OF A RETROVIRAL SYSTEM
JP3524918B2 (en) Lymphokine gene therapy for cancer
Collen et al. Clinical gene transfer studies for hemophilia A
JPH08508415A (en) Systemic gene therapy for connective tissue disease
WO1992015676A1 (en) Somatic cell gene therapy
JPH10287590A (en) Infectious drug supply system
EP0381490B1 (en) Gene therapy using stromal cells
US6140111A (en) Retroviral gene therapy vectors and therapeutic methods based thereon
KR20150069017A (en) Platelet targeted treatment
US6544771B1 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
Hu et al. Codon optimization, expression, and characterization of recombinant lumbrokinase in goat milk
US7867974B2 (en) Induction of tolerance by oral administration of factor VIII and treatment of hemophilia
US20250230466A1 (en) Tissue-specific promoter and use thereof
US20230256026A1 (en) Gene editing for the treatment of epidermolysis bullosa
Hsueh et al. Clinical Protocol of Human Gene Transfer for Hemophilia B. Fudan University, Shanghai, China
WO2020177618A1 (en) Recombinant vectors comprising arylsulfatase a and their uses in stem cell therapy for the treatment of metachromatic leukodystrophy
Qazilbash et al. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome
AU1458200A (en) A myeloid precursor cell useful for gene therapy and for modulation of immune responses
AU709477C (en) Retroviral gene therapy vectors and therapeutic methods based thereon